Frozen Splenocyte Vaccine Potency Assay for Direct Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for determining vaccine potency are slow, subjective, and do not provide a direct measure of immunogenicity, particularly for a broad range of vaccines.
Innovation Solution
A method involving the use of splenocytes from immunized mice, activated with serial dilutions of test and reference vaccines, to determine the number of cells expressing antigen-specific and nonspecific antibodies, using localized labels for differentiation, and comparing dose-response curves to assess vaccine potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If immunodiffusion assays are used to determine vaccine potency, then antibody-reactive materials can be identified, but the process is slow and subjective
Solution Approach 1:
The patent replaces the mechanical immunodiffusion process with an enzyme immunoassay system that uses enzyme-labeled antibodies to detect and quantify vaccine antigens. This substitution eliminates the slow diffusion process and subjective visual assessment, providing faster and more objective results through enzymatic reactions that produce measurable signals.
Solution Approach 2:
The patent utilizes color changes produced by enzyme-labeled antibodies as a detection mechanism. The enzyme reaction generates a colored product whose intensity is proportional to the antigen concentration, enabling rapid and objective quantification of vaccine potency without the slow diffusion process of traditional immunodiffusion assays.
2Measurement precision
If immunodiffusion assays are used to determine vaccine potency, then antigen concentration can be measured, but it does not provide direct indication of immunogenicity
Solution Approach 1:
The patent introduces enzyme-labeled antibodies as intermediaries that bridge antigen detection and immunogenicity assessment. These labeled antibodies not only bind to vaccine antigens for quantification but also enable functional assessment of immunogenicity through the enzyme reaction, preserving both antigen concentration and immunogenicity information simultaneously.
3Measurement precision
If enzyme immunoassay with bactericidal antibodies is used, then specific antigen amount can be quantified, but direct measure of intact preparation immunogenicity is not provided
Solution Approach 1:
The patent creates a multi-functional enzyme immunoassay system that simultaneously performs antigen quantification and immunogenicity assessment. The enzyme-labeled antibodies serve multiple functions: binding to antigens for quantification, producing detectable signals, and preserving information about the intact preparation's immunogenicity, eliminating the need for separate assays.
Data Source
AI summary
Compositions for determining the efficacy and/or potency of a vaccine preparation are described herein. Splenocytes from immunized animals are isolated and can be frozen. Upon thawing such cells are activated by exposure to a series of dilutions of a vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are enumerated, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and/or potency.